Innate Pharma S.A., a globally recognized biotechnology firm at the clinical stage, has formed a partnership with the Institute for Follicular Lymphoma (IFLI), a prominent international non-profit organization, to explore the clinical potential of IPH6501, Innate’s anti-CD20 ANKET, in addressing follicular lymphoma (FL).
The existing phase 1/2 trial undertaken by Innate is an open-label, multicenter study focused on assessing the safety, tolerability, and preliminary anti-tumor properties of IPH6501 in patients with relapsed or refractory CD20-positive Non-Hodgkin lymphoma, now including individuals with relapsed/refractory (R/R) FL.
In order to back the phase 1/2 trial and include patients with FL, IFLI will initially contribute $3 million in acquiring new shares of Innate, which are being issued through a specially reserved capital increase for IFLI at a rate of €1.56 per share, thereby constituting 2.26% of Innate’s share capital.
Conditional upon achieving certain milestones, IFLI may invest an additional $4.9 million into newly issued shares of Innate at a pricing to be established at the time of investment.
“At Innate Pharma, our dedication to pioneering research and development aims to enhance patient outcomes in non-Hodgkin lymphoma, and our partnership with the Institute for Follicular Lymphoma Innovation is a testament to our commitment to developing therapeutic solutions that meet urgent needs and improve the quality of life for those battling this complex illness,” articulated Dr. Sonia Quaratino, Innate Pharma’s Chief Medical Officer.
“IFLI views IPH6501 as holding significant potential for enhancing treatment outcomes in non-Hodgkin lymphomas, including follicular lymphoma,” expressed Dr. Michel Azoulay, IFLI’s Chief Medical Officer. “We are excited to aid Innate in evaluating IPH6501 for FL patients and, upon reaching key milestones, continue to support its future clinical development. This partnership showcases how IFLI’s philanthropic investments can propel advancements in FL treatments.”
The Institute for Follicular Lymphoma Innovation (IFLI) operates as a global non-profit foundation committed to accelerating the advancement of pioneering treatments for FL patients. IFLI actively supports groundbreaking research and technological innovations to lead to the development and market launch of new therapeutics and/or biomarkers for FL treatment and enhance the understanding of FL biology.
Innate Pharma S.A. stands as a global biotechnology entity at the clinical stage, specializing in the development of cancer immunotherapies.